Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’
|dc.identifier.citation||Watts, G. and Norman, R. 2018. Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’ [Editorial]. International Journal of Cardiology. 267: pp: 193-194.|
Seminal data from population genetics have presaged the development of several novel lipid-regulating drugs and the prospect of more effectively addressing high residual risk of cardiovascular disease (CVD) in patients receiving secondary prevention therapies . The most impressive development is the identification of proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of the intracellular cycling of the low-density lipoprotein (LDL) receptor, as a target for lowering LDL-cholesterol (LDL-C) . This journey most recently entered the phase of large scale CV outcome trials . The most widely tested method for inhibiting PCSK9 entails the use of humanized monoclonal antibodies (mAbs) . However, their high acquisition costs and budgeting impact on healthcare are concerning .
In this issue, Kumar et al. report an economic evaluation of PCSK9 inhibitors in Australia . The secondary prevention population relates to the FOURIER trial . Relative to placebo, they estimated an incremental cost-effectiveness ratio (ICER), reporting the cost per quality-adjusted life year (QALY) being higher than $300,000 . The authors concluded that a significant reduction in cost is required to reach the point at which PCSK9 inhibitors can be recommended as cost-effective, an appropriate conclusion. There are a number of considerations, both clinical and economic, pointing to future research for demonstrating cost-effectiveness in specific populations.
|dc.publisher||Elsevier Ireland Ltd.|
|dc.title||Squaring up the health economics of PCSK9 monoclonal antibodies ‘down under’|
|dcterms.source.title||International Journal of Cardiology|
|curtin.department||School of Public Health|
|curtin.contributor.orcid||Norman, Richard [0000-0002-3112-3893]|